Sopharma stock tracks 43 percent sales growth through August

Published on 09/29/2026 at 20:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sopharma stock follows export sales up 68 percent through August. First-half net profit rose 35 percent to more than EUR 52 million.

Sopharma, BG11SOSOBT18, Illustration mit AI erstellt.

Sopharma (ISIN BG11SOSOBT18) reported a 43 percent increase in sales from January through August 2026 compared with the same period of 2025. The company also reported a 1 percent year-over-year sales increase for August, giving investors a fresh view of demand across its domestic and export markets, MarketScreener reported on September 21, 2026.

Exports drive the latest comparison

The sales mix is the key detail. Sopharma said export sales increased 68 percent during the first eight months of 2026 against the year-earlier period, while domestic sales declined 3 percent, according to MarketScreener on September 21, 2026. August added a smaller 4 percent increase in export sales, which partly offset the 3 percent domestic decline in that month.

First half adds scale

The broader first-half picture was stronger than the monthly figure alone suggests. Sopharma reported first-half 2026 revenue of more than EUR 730 million, up more than 11 percent from a year earlier, while net profit rose 35 percent to more than EUR 52 million, IntelliNews reported on September 1, 2026. That combination gives the sales update a useful earnings counterpoint: the company is expanding revenue while also reporting faster net-profit growth for the first six months.

Sopharma produces, distributes and exports pharmaceutical products in Europe, Bulgaria and international markets. Its portfolio includes medicines, food supplements, medical devices and contract manufacturing services, according to Investing.com.

Market value stays substantial

Sopharma had a market capitalization of EUR 1.39 billion on September 28, 2026. The stock's 52-week range was EUR 1.41 to EUR 2.90 on September 25, 2026, providing a dated valuation frame for the sales and earnings figures.

Sales growth shapes the picture

Sopharma stock carried a market capitalization of EUR 1.39 billion on September 28, 2026, while the company had reported 43 percent year-to-date sales growth through August. The contrast between 68 percent export growth and a 3 percent domestic decline makes geographic mix the central operating issue in the latest update.